Termination of immune activation: An essential component of healthy host immune responses

Journal of Innate Immunity

Volumn 6, Issue 6, 2014, Pages 727-738

  Kane, Barry A ^a   Bryant, Katherine J ^a,b   McNeil, H Patrick ^a,b   Tedla, Nicodemus T ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Endocytosis; Immunoreceptor tyrosine based activation motifs; Immunoreceptor tyrosine based inhibitory motifs; Intracellular signalling; Leucocyte immunoglobulin like receptors; Ubiquitination

Indexed keywords

ADAPTOR PROTEIN;

CONSENSUS SEQUENCE; ENDOCYTOSIS; HUMAN; IMMUNE RESPONSE; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; INFLAMMATION; INNATE IMMUNITY; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; IMMUNE SYSTEM; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ENDOCYTOSIS; HUMANS; IMMUNE SYSTEM; IMMUNORECEPTOR TYROSINE-BASED INHIBITION MOTIF; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84908653786     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000363449     Document Type: Review

References (99)

1. Reth M: Antigen receptor tail clue. Nature 1989; 338:383-384.
2. Humphrey MB, Lanier LL, Nakamura MC: Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev 2005; 208:50-65.
3. Latour S, Veillette A: Proximal protein tyro-sine kinases in immunoreceptor signaling. Curr Opin Immunol 2001; 13:299-306.
4. Bounab Y, Getahun A, Cambier J.C., Daëron M: Phosphatase regulation of immunorecep-tor signaling in T cells, B cells and mast cells. Curr Opin Immunol 2013; 25:313-320.
5. Verbrugge A, Meyaard L: Signaling by ITIM-bearing receptors. Curr Immunol Rev 2005; 1: 201-212.
6. Foddor S, Jakus Z, Mocsai A: ITAM-based signalling beyond the adaptive immune response. Immunol Lett 2006; 104:29-37.
7. Staub E, Rosenthal A, Hinzmann B: Systematic identification of immunoreceptor tyro-sine-based inhibitory motifs in the human proteome. Cell Signal 2004; 16:435-456.
8. Brown D, Trowsdale J, Allen R: The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004; 64:215-225.
9. Borges L, Cosman D: LIRs/ILTs/MIRs, inhibitory and stimulatory Igsuperfamily receptors expressed in myeloid and lymphoid cells. Cyto-kine Growth Factor Rev 2000; 11: 209-217.
10. Fanger N, Borges L, Cosman D: The leukocyte immunoglobulin-like receptors (LIRs): a new family of immune regulators. J Leukoc Biol 1999; 66:231-236.
11. Nakajima H, Samaridis J, Angman L., Colon-na M: Cutting edge: human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor γ-chain. J Immunol 1999; 162:5-8.
12. Tedla N, Bandeira-Melo C, Tassinari P., Sloane D, Samplaski M, Cosman D., et al.: Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci USA 2003; 100:1174-1179.
13. Cosman D, Fanger N, Borges L., Kubin M, Chin W, Peterson L., et al.: A novel immuno-globulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7:273-282.
14. An H, Chandra V, Piraino B., Borges L, Geczy C, McNeil H., et al.: Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J Rheumatol 2010; 37:1596-1606.
15. Kuroki K, Tsuchiya N, Shiroishi M., Rasubala L, Yamashita Y, Matsuta K., et al.: Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epi-tope negative rheumatoid arthritis. Hum Mol Genet 2005; 14:2469-2480.
16. Monsivais-Urenda A, Nino-Moreno P, Abud-Mendoza C, Baranda L, Layseca-Espi-nosa E, Lopez-Botet M, et al.: Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J Autoimmun 2007; 29:97-105.
17. Ordonez D, Sanchez AJ, Martinez-Rodriguez JE, Cisneros E., Ramil E, Romo N, et al.: Multiple sclerosis associates with LILRA3 deletion in Spanish patients. Genes Immun 2009; 10: 579-585.
18. Tedla N, An H, Borges L., Vollmer-Conna U, Bryant K, Geczy C., et al.: Expression of activating and inhibitory leukocyte immunoglobu-lin-like receptors in rheumatoid synovium: correlations to disease activity. Tissue Antigens 2011; 77:305-316.
19. Stanietsky N, Mandelboim O: Paired NK cell receptors controlling NK cytotoxicity. FEBS Lett 2010; 584:4895-4900.
20. Nimmerjahn F, Ravetch JV: Fc γ receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47.
21. Van Montfoort N, t Hoen PAC, Mangsbo SM, Camps MGM, Boross P, Melief CJM, et al.: Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells. J Immunol 2012; 189:92-101.
22. Poe JC, Tedder TF: CD22 and Siglec-G in B cell function and tolerance. Trends Immunol 2012; 33:413-420.
23. Walker JA, Smith KGC: CD22: an inhibitory enigma. Immunology 2008; 123:314-325.
24. Lu HK, Mitchell A, Endoh Y., Hampartzou-mian T, Huynh O, Borges L., et al.: LILRA2 selectively modulates LPS-mediated cytokine production and inhibits phagocytosis by monocytes. PLoS One 2012; 7:e33478.
25. Lee DJ, Sieling PA, Ochoa M.T., Krutzik SR, Guo B, Hernandez M, et al.: LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol 2007; 179:8128-8136.
26. Bleharski JR, Li H, Meinken C., Graeber TG, Ochoa MT, Yamamura M, et al.: Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 2003; 301: 1527-1530.
27. van Egmond M, Damen CA, van Spriel AB, Vidarsson G, van Garderen E, van de Winkel JGJ: IgA and the IgA Fc receptor. Trends Immunol 2001; 22:205-211.
28. Pasquier B, Launay P, Kanamaru Y., Moura IC, Pfirsch S, Ruffié C, et al.: Identification of FCαRI as an inhibitory receptor that controls inflammation: dual role of FcRγ ITAM. Immunity 2005; 22:31-42.
29. O'Neill SK, Getahun A, Gauld S.B., Merrell KT, Tamir I, Smith MJ, et al.: Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell an-ergy. Immunity 2011; 35:746-756.
30. Kersh EN, Kersh GJ, Allen PM: Partially phosphorylated T cell receptor ζ molecules can inhibit T cell activation. J Exp Med 1999; 190:1627-1636.
31. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T., Souchet H, Rossato E, et al.: IgG1 and IVIg induce inhibitory ITAM signaling through FCγRIII controlling inflammatory responses. Blood 2012; 119:3084-3096.
32. Barrow AD, Trowsdale J: You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 2006; 36:1646-1653.
33. Hamerman JA, Tchao NK, Lowell C.A., Lanier LL: Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 2005; 6:579-586.
34. Fuchs A, Cella M, Kondo T., Colonna M: Par-adoxic inhibition of human natural interfer-on-producing cells by the activating receptor NKp44. Blood 2005; 106:2076-2082.
35. Blasius AL, Cella M, Maldonado J., Takai T, Colonna M: Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 2006; 107:2474-2476.
36. Thorley-Lawson DA: Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1:75-82.
37. Barrow AD, Astoul E, Floto A., Brooke G, Relou IAM, Jennings NS, et al.: Cutting edge: TREM-like transcript-1, a platelet immuno-receptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2. J Immunol 2004; 172:5838-5842.
38. Allcock RJN, Barrow AD, Forbes S, Beck S., Trowsdale J: The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur J Immunol 2003; 33:567-577.
39. 2-depen-dent pathways. Mol Cell Biol 2005; 25:7181-7192.
40. Ferrand A, Kowalski-Chauvel A, Bertrand C., Escrieut C, Mathieu A, Portolan G., et al.: A novel mechanism for JAK2 activation by a G protein-coupled receptor, the CCK2R: implication of this signaling pathway in pancreatic tumor models. J Biol Chem 2005; 280:10710-10715.
41. Daulhac L, Kowalski-Chauvel A, Pradayrol L., Vaysse N, Seva C: Src-family tyrosine kinases in activation of ERK-1 and p85/p110-phos-phatidylinositol 3-kinase by G/CCKB receptors. J Biol Chem 1999; 274:20657-20663.
42. Kowalski-Chauvel A, Pradayrol L, Vaysse N., Seva C: Gastrin stimulates tyrosine phosphor-ylation of insulin receptor substrate 1 and its association with Grb2 and the phosphati-dylinositol 3-kinase. J Biol Chem 1996; 271: 26356-26361.
43. Munitz A, McBride ML, Bernstein J.S., Rothen-berg ME: A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. Blood 2008; 111:5694-5703.
44. Shlapatska LM, Mikhalap SV, Berdova A.G., Zelensky OM, Yun TJ, Nichols KE, et al.: CD150 association with either the SH2-con-taining inositol phosphatase or the SH2-con-taining protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 2001; 166:5480-5487.
45. Yusa S, Catina TL, Campbell KS: KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol 2004; 172:7385-7392.
46. Avril T, Floyd H, Lopez F., Vivier E, Crocker PR: The membrane-proximal immunorecep-tor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol 2004; 173:6841-6849.
47. Chemnitz JM, Parry RV, Nichols K.E., June CH, Riley JL: SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173:945-954.
48. El Firar A, Voisin T, Rouyer-Fessard C, Ostuni M.A., Couvineau A., Laburthe M: Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis. FASEB J 2009; 23: 4069-4080.
49. Rose-John S, Scheller J, Elson G., Jones SA: Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80:227-236.
50. Levine SJ: Mechanisms of soluble cytokine receptor generation. J Immunol 2004; 173: 5343-5348.
51. Heaney ML, Golde DW: Soluble receptors in human disease. J Leukoc Biol 1998; 64:135-146.
52. Sims JE, Smith DE: The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10: 89-102.
53. Muzio M, Ni J, Feng P., Dixit VM: IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278:1612-1615.
54. Greenfeder SA, Nunes P, Kwee L., Labow M, Chizzonite RA, Ju G: Molecular cloning and characterization of a second subunit of the in-terleukin 1 receptor complex. J Biol Chem 1995; 270:13757-13765.
55. Colotta F, Re F, Muzio M., Bertini R, Polenta-rutti N, Sironi M, et al.: Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261:472-475.
56. Qin J, Qian Y, Yao J., Grace C, Li X: SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 2005; 280: 25233-25241.
57. Lee KM, Nibbs RJB, Graham GJ: D6: the 'crowd controller' at the immune gateway. Trends Immunol 2013; 34:7-12.
58. Pitti RM, Marsters SA, Lawrence D.A., Roy M., Kischkel FC, Dowd P, et al.: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396:699-703.
59. Boyce BF, Xing L: Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9(SUPPL. 1):S1.
60. Ferrara N, Gerber H-P, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
61. Malynn BA, Ma A: Ubiquitin makes its mark on immune regulation. Immunity 2010; 33: 843-852.
62. Sun SC: Deubiquitylation and regulation of the immune response. Nat Rev Immunol 2008; 8:501-511.
63. Komander D, Rape M: The ubiquitin code. Annu Rev Biochem 2012; 81:203-229.
64. Bhoj VG, Chen ZJ: Ubiquitylation in innate and adaptive immunity. Nature 2009; 458: 430-437.
65. Renner F, Schmitz ML: Autoregulatory feedback loops terminating the NF-κB response. Trends Biochem Sci 2009; 34:128-135.
66. Conze DB, Wu CJ, Thomas J.A., Landstrom A., Ashwell JD: Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kap-paB activation. Mol Cell Biol 2008; 28:3538-3547.
67. Schneider M, Zimmermann AG, Roberts R.A., Zhang L., Swanson KV, Wen H, et al.: The innate immune sensor NLRC3 attenuates Tolllike receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol 2012; 13: 823-831.
68. Allen IC, Moore CB, Schneider M, Lei Y., Davis BK, Scull MA, et al.: NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. Immunity 2011; 34:854-865.
69. Castanier C, Zemirli N, Portier A., Garcin D, Bidere N, Vazquez A., et al.: MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors. BMC Biol 2012; 10: 44.
70. Kawai T, Akira S: TLR signaling. Cell Death Differ 2006; 13:816-825.
71. O'Neill LA, Golenbock D, Bowie AG: The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 2013; 13:453-460.
72. Liew FY, Xu D, Brint E.K., O'Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5: 446-458.
73. Yuk JM, Shin DM, Lee H.M., Kim JJ, Kim SW, Jin HS, et al.: The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat Immunol 2011; 12:742-751.
74. Janssens S, Burns K, Tschopp J., Beyaert R: Regulation of interleukin-1- and lipopolysac-charide-induced NF-kappaB activation by alternative splicing of MyD88. Curr Biol 2002; 12:467-471.
75. Janssens S, Burns K, Vercammen E., Tschopp J, Beyaert R: MyD88S, a splice variant of MyD88, differentially modulates NF-κB- and AP-1-dependent gene expression. FEBS Lett 2003; 548:103-107.
76. Kobayashi K, Hernandez LD, Galán JE, Jane-way CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110:191-202.
77. Carty M, Goodbody R, Schroder M., Stack J, Moynagh PN, Bowie AG: The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006; 7:1074-1081.
78. Ahmed S, Maratha A, Butt A.Q., Shevlin E., Miggin SM: TRIF-mediated TLR3 and TLR4 signaling is negatively regulated by ADAM15. J Immunol 2013; 190:2217-2228.
79. Yang Y, Liao B, Wang S., Yan B, Jin Y, Shu H.B., et al.: E3 ligase WWP2 negatively regulates TLR3-mediated innate immune response by targeting TRIF for ubiquitination and degradation. Proc Natl Acad Sci USA 2013; 110: 5115-5120.
80. Xue Q, Zhou Z, Lei X., Liu X, He B, Wang J., et al.: TRIM38 negatively regulates TLR3-medi-ated IFN-β signaling by targeting TRIF for degradation. PLoS One 2012; 7:e46825.
81. Shimazu R, Akashi S, Ogata H., Nagai Y, Fukudome K, Miyake K., et al.: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-1782.
82. Chang J, Kunkel SL, Chang CH: Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Proc Natl Acad Sci USA 2009; 106:18327-18332.
83. Matsumura T, Hayashi H, Takii T., Thorn CF, Whitehead AS, Inoue J, et al.: TGF-beta down-regulates IL-1alpha-induced TLR2 expression in murine hepatocytes. J Leukoc Biol 2004; 75:1056-1061.
84. Divanovic S, Trompette A, Atabani S.F., Madan R., Golenbock DT, Visintin A, et al.: Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J Endotoxin Res 2005; 11:363-368.
85. Divanovic S, Trompette A, Atabani S.F., Madan R., Golenbock DT, Visintin A, et al.: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 2005; 6:571-578.
86. Sun L, Ye RD: Role of G protein-coupled receptors in inflammation. Acta Pharmacol Sin 2012; 33:342-350.
87. Magalhaes AC, Dunn H, Ferguson SSG: Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol 2012; 165:1717-1736.
88. Ferguson SSG: Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53:1-24.
89. Spat A, Hunyady L: Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84:489-539.
90. Nakayama M, Nakayama A, van Lessen M, Yamamoto H, Hoffmann S., Drexler HCA, et al.: Spatial regulation of VEGF receptor endo-cytosis in angiogenesis. Nat Cell Biol 2013; 15: 249-260.
91. Takayama Y, May P, Anderson RGW, Herz J: Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor β (PDGFRβ). J Biol Chem 2005; 280:18504-18510.
92. Maskrey BH, Megson IL, Whitfield P.D., Rossi AG: Mechanisms of resolution of inflammation: a focus on cardiovascular disease. Arte-rioscler Thromb Vasc Biol 2011; 31:1001-1006.
93. Serhan CN, Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6:1191-1197.
94. Serhan CN: The resolution of inflammation: the devil in the flask and in the details. FASEB J 2011; 25:1441-1448.
95. Spite M, Serhan CN: Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107:1170-1184.
96. Fredman G, Li Y, Dalli J., Chiang N, Serhan CN: Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci Rep 2012; 2:639.
97. Perretti M, D'Acquisto F: Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009, 9: 62-70.
98. Kobayashi Y: The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J Leukoc Biol 2010; 88:1157-1162.
99. Hiroshima Y, Hsu K, Tedla N., Chung YM, Chow S, Herbert C, Geczy CL: S100A8 induces IL-10 and protects against acute lung injury. J Immunol 2014; 192:2800-2811.